Patient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: A cohort study

BMC Medicine

Volumn 7, Issue , 2009, Pages

  Egwaga, Saidi ^a   Mkopi, Abdallah ^b   Range, Nyagosya ^c   Haag Arbenz, Vera ^d   Baraka, Amuri ^b   Grewal, Penny ^d   Cobelens, Frank ^e,f   Mshinda, Hassan ^b   Lwilla, Fred ^a   Van Leth, Frank ^e,f  

^a MINISTRY OF HEALTH AND SOCIAL WELFARE   (Tanzania)

^b IFAKARA HEALTH INSTITUTE   (Tanzania)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^d NOVARTIS PHARMA AG   (Switzerland)

^e KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY CONTROL; RISK ASSESSMENT; TANZANIA; TREATMENT RESPONSE; TUBERCULOSIS; CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; DIRECTLY OBSERVED THERAPY; ETHAMBUTOL; HUMANS; ISONIAZID; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN; TANZANIA; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 74049090121     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-7-80     Document Type: Article

References (28)

1. World Health Organization Global Tuberculosis Control: Surveillance, Planning, Financing. 2008, Geneva: WHO.
2. Cobelens FG, Egwaga SM, van Ginkel T, Muwinge H, Matee MI, Borgdorff MW. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis 2006, 43(5):634-639. 10.1086/506432, 16886159.
3. World Health Organization Treatment of Tuberculosis: Guidelines for National Programmes 2003, Geneva: WHO, 3.
4. Enarson DA, Rieder HL, Arnadottir T, Trébucq A. Management of Tuberculosis: A Guide for Low Income Countries. 2000, Paris: International Union Against Tuberculosis and Lung Disease, 5.
5. World Health Organization Anti-tuberculosis Drug Resistance in the World: Fourth Global Report. 2008, Geneva: WHO.
6. Blondal K. Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis. Bull World Health Organ 2007, 85(5):387-390. discussion 391-384, 10.2471/BLT.06.035345, 2636665, 17639225.
7. Churchyard GJ, Corbett EL, Kleinschmidt I, Mulder D, De Cock KM. Drug-resistant tuberculosis in South African gold miners: incidence and associated factors. Int J Tuberc Lung Dis 2000, 4(5):433-440.
8. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis S, King B, Mangura B. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006, 173(3):350-356. 10.1164/rccm.200503-417OC, 16109981.
9. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001, 32(4):623-632. 10.1086/318706, 11181127.
10. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997, 337(12):801-808. 10.1056/NEJM199709183371201, 9295239.
11. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003, 37(1):101-112. 10.1086/375220, 12830415.
12. Wandwalo E, Kapalata N, Egwaga S, Morkve O. Effectiveness of community-based directly observed treatment for tuberculosis in an urban setting in Tanzania: a randomised controlled trial. Int J Tuberc Lung Dis 2004, 8(10):1248-1254.
13. Lwilla F, Schellenberg D, Masanja H, Acosta C, Galindo C, Aponte J, Egwaga S, Njako B, Ascaso C, Tanner M. Evaluation of efficacy of community-based vs. institutional-based direct observed short-course treatment for the control of tuberculosis in Kilombero district, Tanzania. Trop Med Int Health 2003, 8(3):204-210. 10.1046/j.1365-3156.2003.00999.x, 12631309.
14. Adatu F, Odeke R, Mugenyi M, Gargioni G, McCray E, Schneider E, Maher D. Implementation of the DOTS strategy for tuberculosis control in rural Kiboga District, Uganda, offering patients the option of treatment supervision in the community, 1998-1999. Int J Tuberc Lung Dis 2003, 7(9 Suppl 1):S63-71.
15. Akkslip S, Rasmithat S, Maher D, Sawert H. Direct observation of tuberculosis treatment by supervised family members in Yasothorn Province, Thailand. Int J Tuberc Lung Dis 1999, 3(12):1061-1065.
16. Manders AJ, Banerjee A, Borne HW, Harries AD, Kok GJ, Salaniponi FM. Can guardians supervise TB treatment as well as health workers? A study on adherence during the intensive phase. Int J Tuberc Lung Dis 2001, 5(9):838-842.
17. Newell JN, Baral SC, Pande SB, Bam DS, Malla P. Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. Lancet 2006, 367(9514):903-909. 10.1016/S0140-6736(06)68380-3, 16546538.
18. Wright J, Walley J, Philip A, Pushpananthan S, Dlamini E, Newell J, Dlamini S. Direct observation of treatment for tuberculosis: a randomized controlled trial of community health workers versus family members. Trop Med Int Health 2004, 9(5):559-565. 10.1111/j.1365-3156.2004.01230.x, 15117299.
19. Walley JD, Khan MA, Newell JN, Khan MH. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet 2001, 357(9257):664-669. 10.1016/S0140-6736(00)04129-5, 11247549.
20. World Health Organization Community involvement in tuberculosis care and prevention. 2008, Geneva: WHO.
21. Frieden TR, Sbarbaro JA. Promoting adherence to treatment for tuberculosis: the importance of direct observation. Bull World Health Organ 2007, 85(5):407-409. 10.2471/BLT.06.038927, 2636637, 17639230.
22. Thiam S, LeFevre AM, Hane F, Ndiaye A, Ba F, Fielding KL, Ndir M, Lienhardt C. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA 2007, 297(4):380-386. 10.1001/jama.297.4.380, 17244834.
23. Pungrassami P, Johnsen SP, Chongsuvivatwong V, Olsen J, Sorensen HT. Practice of directly observed treatment (DOT) for tuberculosis in southern Thailand: comparison between different types of DOT observers. Int J Tuberc Lung Dis 2002, 6(5):389-395.
24. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ 2001, 79(1):61-68. 2566330, 11217670.
25. Macq JC, Theobald S, Dick J, Dembele M. An exploration of the concept of directly observed treatment (DOT) for tuberculosis patients: from a uniform to a customised approach. Int J Tuberc Lung Dis 2003, 7(2):103-109.
26. MacIntyre CR, Goebel K, Brown GV, Skull S, Starr M, Fullinfaw RO. A randomised controlled clinical trial of the efficacy of family-based direct observation of anti-tuberculosis treatment in an urban, developed-country setting. Int J Tuberc Lung Dis 2003, 7(9):848-854.
27. Abaasa AM, Todd J, Ekoru K, Kalyango JN, Levin J, Odeke E, Karamagi CA. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res 2008, 8:241. 10.1186/1472-6963-8-241, 2606686, 19021908.
28. Weidle PJ, Wamai N, Solberg P, Liechty C, Sendagala S, Were W, Mermin J, Buchacz K, Behumbiize P, Ransom RL. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006, 368:1587-1594. 10.1016/S0140-6736(06)69118-6, 17084759.